Bioalliance Pharma

BioAlliance Pharma (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.

To attack the challenge of resistance, the company has multiple product opportunities in two broad proprietary drug delivery systems represented by the Lauriad® adhesive technology and the Transdrug® nanoparticle technology . Together with a New Chemical Entities (NCE) program of molecules being developed as new drugs in oncology and HIV, the company is able to address worldwide markets in the EU, U.S, and Asia.